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Abstract
Objective: Adiponectin (APN) is an anti-inflammatory hormone derived from adipose tissue that attenuates acute lung
injury in rodents. In this study, we investigated the association between circulating APN and outcomes among patients with
acute respiratory distress syndrome (ARDS).
Methods: We performed a retrospective cohort study using data and plasma samples from participants in the multicenter
ARDS Network Fluid and Catheter Treatment Trial.
Results: Plasma APN concentrations were measured in 816 (81.6%) trial participants at baseline and in 568 (56.8%) subjects
at both baseline and day 7 after enrollment. Clinical factors associated with baseline APN levels in multivariable-adjusted
models included sex, body mass index, past medical history of cirrhosis, and central venous pressure (model R2 = 9.7%). We
did not observe an association between baseline APN and either severity of illness (APACHE III) or extent of lung injury
(Lung Injury Score). Among patients who received right heart catheterization (n = 384), baseline APN was inversely related to
mean pulmonary artery pressure (b=20.015, R2 1.5%, p = 0.02); however, this association did not persist in multivariable
models (b=20.009, R2 0.5%, p = 0.20). Neither baseline APN levels [HR per quartile1.04 (95% CI 0.91–1.18), p = 0.61], nor
change in APN level from baseline to day 7 [HR 1.04 (95% CI 0.89–1.23), p = 0.62)] were associated with 60 day mortality in
Cox proportional hazards regression models. However, subgroup analysis identified an association between APN and
mortality among patients who developed ARDS from extra-pulmonary etiologies [HR per quartile 1.31 (95% CI 1.08–1.57)].
APN levels did not correlate with mortality among patients developing ARDS in association with direct pulmonary injury [HR
0.96 (95% CI 0.83–1.13)], pinteraction = 0.016.
Conclusions: Plasma APN levels did not correlate with disease severity or mortality in a large cohort of patients with ARDS.
However, higher APN levels were associated with increased mortality among patients developing ARDS from extra-
pulmonary etiologies.
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Introduction
Adiponectin (APN) is a highly abundant circulating hormone
with pleotrophic effects upon diverse pulmonary cell types [1–4]
including alveolar macrophages, epithelium, and vascular endo-
thelium [3,5,6]. Though principally derived from adipocytes,
circulating APN levels are paradoxically increased in lean
individuals and decreased in subjects with higher body mass
indexes [7]. In the lung, APN has been shown to have important
anti-inflammatory and vascular protective actions, prompting pre-
clinical studies examining the role of APN in the pathogenesis of
pulmonary disorders including acute respiratory distress syndrome
(ARDS) [2–4,8]
ARDS is an acute, life-threatening lung condition involving
immune and endothelial cell activation that develops in association
with direct (e.g. pneumonia) and indirect pulmonary (e.g.,
urosepsis) challenges [9]. Although the role of circulating APN
in human ARDS has not yet been investigated, animal studies
suggest a causal link between hypoadiponectemia and ARDS
pathogenesis. For example, APN-deficient mice have a markedly
increased susceptibility to developing acute lung injury (the murine
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equivalent of ARDS) [2,4,6,8] and this susceptibility is attenuated
following APN replacement [3]. Further, mice deficient in APN
are prone to developing pulmonary vascular abnormalities
including elevated pulmonary artery pressures [5], a hemodynam-
ic alteration associated with increased mortality among patients
with ARDS [10]. Together, these pre-clinical findings prompted
our current investigation into the relationship of circulating APN
to outcomes in ARDS.
Materials and Methods
Data Source
We used National Heart, Lung and Blood Institute (NHLBI)
ARDS Network Fluid and Catheter Treatment Trial (FACTT)
Trial [11,12] research materials obtained from the NHLBI
Biologic Specimen and Data Repository Information Coordinat-
ing Center (BioLINCC). The ARDS Network is comprised of 42
hospitals across the United States; details regarding protocols of
ARDS Network studies can be found at the ARDSNet.org
website. The FACTT trial was a 262 factorial design, which
randomized patients with ARDS to receive either a right heart
catheter or a central venous catheter [12] and either conservative
or liberal fluid management [11,13]. Patients receiving conserva-
tive fluid management had overall fewer days of mechanical
ventilation but otherwise outcomes did not differ significantly
between groups. For our study, all analyses and procedures were
approved by the Boston University School of Medicine, the
Thomas Jefferson University School of Medicine Institutional
Review Boards and NHLBI BioLINCC.
Covariates and outcomes
Baseline covariates were measured at FACTT enrollment,
which was within 48 hours of the development of ARDS. Data
obtained from trial participants included demographics (age, race,
sex), anthropometrics (body mass index, height, weight), comorbid
conditions (HIV/Acquired Immunodeficiency Syndrome, arthri-
tis, chronic pulmonary disease, cirrhosis, dementia, diabetes
mellitus, dialysis dependence, alcohol abuse, congestive heart
failure, hepatic encephalopathy, hypertension, immunosuppres-
sion, leukemia, lymphoma, myocardial infarction, stroke, meta-
static solid tumor, peptic ulcer, peripheral vascular disease), vital
signs (blood pressure, heart rate, central venous pressure, fluid
intake and output, PaO2/FiO2, vasopressor requirement), labora-
tory values (albumin, bicarbonate, blood urea nitrogen, chloride,
creatinine, glucose, hemoglobin, platelets, potassium, sodium,
protein and white blood cell count), Murray lung injury score (a
composite radiographic appearance, oxygenation, PEEP level and
lung compliance) [14], and baseline Acute Physiology and Chronic
Health Evaluation (APACHE) III score [15]. Among patients
randomized to receive a right heart catheterization, recordings of
pulmonary artery pressures, pulmonary artery occlusion pressure,
cardiac index and transpulmonary pressure gradient (mean
pulmonary pressure minus pulmonary artery occlusion pressure)
were also utilized. Patients were followed for up to 60 days for
outcome of ‘death prior to discharge home with unassisted
breathing’.
Adiponectin measurements
Plasma APN concentration was measured by enzyme-linked
immunosorbent assay using a commercially available kit (R&D
Systems, Minneapolis, MN) according to company protocol. All
plasma samples were diluted 1:200 in serum diluting buffer prior
to assessing APN concentrations.
Statistical Analyses
The distribution of clinical variables among APN quartiles was
compared using Kruskal-Wallis testing and Mantel-Haenzel tests,
as appropriate. In order to determine clinical factors associated
with APN, variables that were nominally associated with APN
levels in univariate analyses (p,0.10) were entered into multivar-
iable linear regression with backward selection (p,0.10). Given a
priori associations of age with APN levels and clinical outcomes,
age was forced into adjusted models that did not include APACHE
scores (which are calculated using age). We excluded variables
with .15% missing data from inclusion in multivariable models.
APN and change in APN were log-transformed and used as
dependent variables in multivariable linear regression analyses.
We specifically explored the associations between APN and
pulmonary hemodynamics, as well as APN and lung injury scores
in multivariable models after adjusting for other clinical factors
associated with APN. Separate analyses were performed for
clinical factors at baseline and for the change in clinical variables
from baseline to day 7. We explored the association of APN with
60-day mortality in Cox proportional hazards models using
quartiles of APN levels and clinical variables associated with APN
as independent variables. We examined the association of APN
with 60-day mortality and quartiles of change in APN (among
patients surviving to day 7) in a similar manner. Secondary models
that included APN and other variables as time-varying covariates
in Cox proportional hazards models were also evaluated. Because
of the role of APN in attenuating endothelial activation in animal
models of acute lung injury [3], we performed an exploratory
subgroup analysis investigating the association between APN and
mortality stratifying patients by either ‘‘direct’’ pulmonary injury
(eg., pneumonia, aspiration) or ‘‘indirect’’ injury from extra-
pulmonary etiologies (eg., urosepsis, trauma, transfusion) [16]. We
used Kaplan-Meier survival plots with log-rank tests to visually
demonstrate the association between APN and mortality and
report 60day mortality rates generated from the Kaplan-Meier
survival function. Finally, we examined Spearman rank correla-
tions between APN and log-transformed ventilator-free days, a
composite outcome of duration of mechanical ventilation and
mortality [17]. In order to examine whether multiple hypothesis
testing might better explain significant (at alpha= 0.05) associa-
tions between APN and clinical variables, univariate associations
between clinical factors and APN levels were examined in a
sensitivity analysis using a Bonferonni-adjusted threshold of
p = 0.001 (derived from alpha 0.05/50 tests).
Given that a prior study of critically ill patients with respiratory
failure demonstrated an odds ratio for 28-day mortality of 1.59
associated for each 5 ug/ml increase in total APN [18], we
estimated a power of 82% with alpha= 0.05 to detect similar
association in the current study. All analyses were performed using
SAS 9.1 (Cary, NC, USA), with alpha of 0.05.
Results
Patient characteristics
Of 1000 FACTT trial participants, plasma was available from
827 subjects at baseline, of whom 816 (81.6%) had detectable APN
levels, and from 568 (56.8%) subjects at both baseline and day 7
after enrollment. Trial participants were on average 49.8616
years old, 53% were male, and 64% were white, with 60-day
mortality of 26.8% (219/816). Compared to patients from whom
plasma was available, the 184 subjects that were not studied had
similar distributions of age (p = 0.92), sex (p = 1.0), race (p = 0.39),
etiology of ARDS (p= 0.24), and APACHE III score (p = 0.10).
Among the 248 patients who provided baseline but not day 7
Adiponectin and ARDS
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plasma samples, 149 (60%) remained hospitalized at day 7, 24
(10%) were discharged home prior to day 7, and 75 (30%) died
prior to day 7.
Adiponectin and Clinical Factors
Analysis of plasma APN levels showed that median APN levels
increased over the course of hospitalization: baseline [7245 pg/ml
(IQR 3610–13288)], day 7 [9451 pg/ml (IQR 5038–15576)] and
change from baseline to day 7 [1346 pg/ml (IQR 22194–5879),
p,0.001]. Demographic and clinical characteristics grouped
according to baseline APN quartiles are shown in Table S1 in
File S1. Factors associated with baseline APN levels after
inclusion in multivariable-adjusted models included sex, body
mass index, past medical history of cirrhosis, and central venous
pressure (Table 1, N= 666, model R2= 9.7%). Baseline APN
levels were not associated with APACHE III critical illness severity
scores, Murray lung injury scores, or measures of oxygenation
(PaO2/FiO2 ratio). Factors associated with change in APN level
from baseline to day 7 are shown in Table S2 in File S1. In
multivariable analysis, only a history of cirrhosis (b=20.28,
R2= 0.84%, p,0.04) was associated with change in APN from
baseline to day 7.
Table 2 demonstrates the association between baseline APN
levels and pulmonary hemodynamic variables among 384 patients
who were randomized to receive a pulmonary artery catheter.
Baseline APN levels were inversely associated with mean
pulmonary arterial pressure (b=20.015, R2= 1.5%, p= 0.02)
but not with other measures of pulmonary vascular hemodynamics
such as transpulmonary pressure, pulmonary artery occlusion
pressure or cardiac index. After adjusting for age, race, sex, body
mass index, and relevant clinical factors (ie., PEEP, cirrhosis, HIV)
association between mean pulmonary artery pressure and baseline
APN was attenuated (b=20.009, R2= 0.5%, p= 0.20).
Adiponectin and Outcomes
When analyzing all subjects, neither baseline APN levels [APN
quartile 4: 43% Kaplan-Meier mortality estimate vs. quartile 1:
36% mortality (Figure 1); HR per APN quartile1.04 (95% CI
0.91–1.18), p = 0.61;], change in APN from baseline to day 7 [HR
1.04 (0.89–1.23), p = 0.62)] nor analysis of APN as a time-varying
covariate [HR for ln APN 1.13 (0.99–1.30) p = 0.07] were
significantly associated with 60 day mortality. Further, we did
not identify an association between baseline APN and ventilator-
free days (R2 = 0.14%, p= 0.29).
To further explore the relationship between APN and mortality
we stratified patients based on whether the etiology of ARDS came
from direct or indirect lung injury. Patients with indirect lung
injury [median 5909 pg/ml (IQR 3332–12127)] had significantly
lower baseline APN levels than those with direct lung injury
[7784 pg/ml (IQR 4122–14274)] p = 0.004. We observed a
significant association between baseline APN levels and mortality
among patients with indirect etiologies for ARDS [N=322, APN
quartile 4: 56% Kaplan-Meier mortality vs. quartile 1:34%
(Figure 2); HR per APN quartile 1.31 (95% CI 1.08–1.57)]. In
contrast, we did not identify an association between APN and
mortality among patients developing ARDS in association with
direct pulmonary injury [N=494, APN quartile 4:36% Kaplan-
Meier mortality vs. quartile 1: 37% (Figure 3); HR per APN
quartile 0.96 (95% CI 0.83–1.13)], p interaction= 0.016. Among
patients with indirect lung injuries, the association between
baseline APN and mortality persisted after adjustment for age,
race, sex, and body mass index [HR per APN quartile 1.29 (95%
CI 1.05–1.58)], but this was attenuated after further adjusting for
APACHE III score, central venous pressure and positive end
expiratory pressure [HR per APN quartile 1.18(95% CI 0.94–
1.49)]. No significant interaction was seen for the association
between change in APN levels from baseline to day 7, mortality
and mechanism of lung injury (p interaction= 0.63).
Discussion
We investigated the clinical correlates and outcomes associated
with plasma APN levels in more than 800 patients with well-
classified ARDS. In addition to confirming previously-described
associations between APN with sex and body mass index, we
identified a novel correlation between APN levels and central
venous pressures. We did not find a relationship between plasma
APN levels and severity of illness or lung injury as measured by
either the APACHE III score or the Murray Lung Injury score.
Moreover, associations between APN and mean pulmonary
arterial pressure did not persist after adjusting for demographic
and clinical variables. Consistent with prior studies of critically ill
patients [18,19], we found that plasma APN levels were higher at
late time points in ARDS when compared to the onset of disease.
Surprisingly, neither baseline nor dynamic changes in APN levels
were associated with mortality among all patients with ARDS in
the present study. However, subgroup analysis showed an
association between baseline APN levels (but not changes in
APN) and mortality in patients who developed ARDS with extra-
pulmonary etiologies.
Animal studies have demonstrated that hypoadiponectinemia
predisposes to the onset of acute lung injury and increases the
severity of disease [2–4,8]. However, we are unaware of prior
studies examining circulating APN levels, clinical factors, and
outcomes in human ARDS. Ahasic et al recently showed that an
Table 1. Multivariable-adjusted model of factors associated with baseline adiponectin levels.
Variable Beta estimate Partial R2 p-value
Age (per year) 0.0045 0.005 0.069
Male sex 20.3213 0.026 ,0.0001
Body mass index 20.022 0.027 ,0.0001
AIDS 0.2626 0.005 0.083
Cirrhosis 0.6903 0.017 0.001
Central venous pressure 20.0207 0.009 0.015
Positive end expiratory pressure 20.0191 0.006 0.054
Model N= 666, Model R2 = 0.097.
doi:10.1371/journal.pone.0108561.t001
Adiponectin and ARDS
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e108561
APN gene polymorphism rs2082940 was associated with poor
outcomes in ARDS, but circulating APN levels were not measured
in this study [20]. In a single center cohort of 175 mechanically
ventilated patients of diverse diagnoses (21% with ARDS), we
previously showed that higher APN levels at study enrollment were
associated with increased mortality [18]. Similarly, in a population
of 170 critically ill patients Koch et al. reported that higher plasma
APN levels measured early in the course disease were predictive of
increased mortality [21]. In our current investigation we did not
identify an association between plasma APN and mortality among
all patients with ARDS, although we observed a positive
correlation among patients with extra-pulmonary etiologies for
ARDS. Our subgroup analysis may explain why previous studies
have reported a positive association between APN and mortality
among critically ill subjects, as extra-pulmonary conditions were
more prevalent in the general intensive care unit populations in
prior studies [18,21].
The clinical observations that higher APN levels are associated
with poor outcomes appear to conflict with experimental findings
in rodents, which have consistently shown a relationship between
Table 2. Pulmonary artery catheter hemodynamics and adiponectin levels.
Baseline Adiponectin Quartile
Pulmonary artery
catheter value
Quartile 1
(95–3364 pg/ml) N=96
Quartile 2
(3380–7164) N=96
Quartile 3
(7202–13954) N=96
Quartile 4
(13974–60336) N=96 p
Pulmonary artery systolic
pressure (mmHg)
42 (37–51) 40 (34–48) 39 (33–46) 41 (33–49) 0.038
Pulmonary artery diastolic
pressure (mmHg)
23 (20–28) 21 (16–26) 22 (17–26) 21 (17–25) 0.013
Mean pulmonary artery
pressure (mmHg)
30 (27–35) 27 (23–33) 27 (23–32) 28 (22–33) 0.01*
Pulmonary artery occlusion
pressure (mmHg)
16 (12–20) 15 (10–18) 15 (12–18) 15 (11–18) 0.23
Trans-pulmonary pressure
gradient (mm Hg)
14.3 (11.3–18) 13.5 (8.8–17) 12.7 (9.3–16.8) 12.7 (8.7–15.7) 0.12
Cardiac Index (l/min/m2) 4.1 (3.4–4.8) 3.8 (3.2–4.4) 3.7 (3.0–4.8) 4.1 (3.1–5.1) 0.23
Values are medians (Inter-Quartile Range).
Trans-pulmonary pressure gradient: Mean pulmonary artery pressure-Pulmonary artery occlusion pressure.
*p,0.1 and selected for inclusion in multivariable models.
doi:10.1371/journal.pone.0108561.t002
Figure 1. Kaplan-Meier survival plot demonstrating 60-day mortality for patients with acute respiratory distress syndrome
stratified by quartile of baseline adiponectin (APN) level for full cohort (N=816). APN Quartile 1: 95–3589 pg/ml; Quartile 2: 3630–
7241 pg/ml; Quartile 3: 7248–13212; Quartile 4: 7248–13212.
doi:10.1371/journal.pone.0108561.g001
Adiponectin and ARDS
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Figure 2. Kaplan-Meier survival plots demonstrating 60-day mortality for patients with acute respiratory distress syndrome
stratified by quartile of baseline adiponectin (APN) level for patients with indirect lung injury (N=322). A significant interaction was
demonstrated (p = 0.016) for the association between baseline APN levels and mortality based on whether the mechanism of acute respiratory
distress syndrome was presumed to be from ‘‘direct’’ pulmonary injury (eg., pneumonia, aspiration) or ‘‘indirect’’ injury from extra-pulmonary
etiologies (eg., urosepsis, trauma, transfusion).
doi:10.1371/journal.pone.0108561.g002
Figure 3. Kaplan-Meier survival plots demonstrating 60-day mortality for patients with acute respiratory distress syndrome
stratified by quartile of baseline adiponectin (APN) level for patients with direct lung injury (N=494).
doi:10.1371/journal.pone.0108561.g003
Adiponectin and ARDS
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low adiponectin states (ie, knockout mice) and poor outcomes in
acute lung injury [2,4,6,8]. However, in pre-clinical rodent studies
(e.g. knock-out mice) changes in APN levels occur prior to the
onset of disease, whereas in human studies APN levels are
examined after disease onset. Thus, we postulate that higher APN
levels in patients early after onset of an acute illness may represent
a dysregulated immune response. We propose that future studies
exploring this hypothesis focus on patients with extrapulmonary
etiologies of ARDS, in whom APN-endothelial [3,16] interactions
may be of greater importance.
Our study confirmed prior associations of plasma APN levels
with female sex, low body mass index, and cirrhosis [18,21].
Additionally, we identified a novel association between plasma
APN levels and central venous pressure. Although this observation
was unanticipated, results are consistent with findings in other
studies showing that APN acts on systemic blood vessels to increase
nitric oxide production and decrease vascular tone [22]. We
hypothesize that increased nitric oxide production might partly
explain why lower central venous pressures were observed in
patients with higher APN levels in our study.
This study has a number of strengths and several limitations.
The most obvious strengths are that analyses were performed on a
large number of samples and that detailed clinical characteristics
were available for all subjects enrolled in our study. While a robust
database provided us with sufficient power to detect moderate
associations between APN and clinical factors, we recognize that
more subtle associations might have been missed by our analyses.
We also acknowledge that when testing multiple clinical factors to
identify associations there is a greater risk of type I errors.
However, our results would not have significantly changed with
use of p-values corrected for multiple hypothesis tests. In addition,
our analysis of the association between patient outcomes and
changes in APN levels over time may have been affected by
selection bias; patients without APN levels available on day 7 were
more likely to have died prior to day 7 than patients available for
sample collection. Measurement of daily APN may better
demonstrate associations between temporal changes in APN and
clinical outcomes in future studies. One other limitation of our
study is that only total APN levels were measured in our samples.
Since APN is known to circulate in at least three functionally
distinct isoforms [23,24] it is plausible that changes in individual
APN isoforms may have more strongly correlated with outcomes
in our study. In addition, analyses among subgroups of ARDS
etiology were exploratory and should be considered hypothesis-
generating. Lastly, as with all observational studies, causal
inference for associations between clinical factors and APN levels
is limited.
In conclusion, our study fills multiple knowledge gaps regarding
the relationship between APN, clinical factors and clinical
outcomes in ARDS. Although we did not observe significant
associations between plasma APN and mortality in the entire
cohort of patients, we identified novel clinical correlates of APN.
Our analysis demonstrates an interaction between the mechanism
of lung injury and the association of APN with mortality, a finding
that is supported by experimental evidence and argues for further
clinical investigation examining the role of APN in patients with
indirect causes of ARDS.
Supporting Information
File S1 Legend. Table S1. Baseline clinical and demographic
characteristics of patients with ARDS according to baseline
adiponectin quartile. Table S2. Characteristics Associated with
Change in Adiponectin from Baseline (day 0) to Day 7.
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